COMMUNIQUÉS West-GlobeNewswire

Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/05/2026
ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs [...]
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
11/05/2026
Delivered Q1 2026 Total Revenues of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of [...]
SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
11/05/2026
Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA First Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $ [...]
Oculis Reports Q1 2026 Financial Results and Provides Company Update
11/05/2026
Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026 Licaminlimab PREDICT-1 Trial in Active Site Recruitment Phase, [...]
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
11/05/2026
– LOQTORZI ® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug [...]
Ceribell Reports First Quarter 2026 Financial Results
11/05/2026
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
11/05/2026
First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in [...]
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
11/05/2026
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis [...]
Harrow Announces First Quarter 2026 Financial Results
11/05/2026
First Quarter 2026 and Selected Highlights: VEVYE ® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE demand growth on track to [...]
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
11/05/2026
On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights [...]
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
11/05/2026
Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later this year, including [...]
Outset Medical to Present at RBC Global Healthcare Conference
11/05/2026
SAN JOSE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less [...]
Abivax Announces Results of its May 11, 2026 Annual General Meeting
11/05/2026
Abivax Announces Results of its May 11, 2026 Annual General Meeting PARIS, France – May 11, 2026 – 10:05 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical- [...]
Oculis Reports Q1 2026 Financial Results and Provides Company Update
11/05/2026
ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026 Licaminlimab [...]
CVRx Reports First Quarter 2026 Financial and Operating Results
11/05/2026
MINNEAPOLIS, May 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Sangamo Therapeutics Announces First Quarter 2026 Earnings Call
11/05/2026
RICHMOND, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company today announced that the company has scheduled the release of its first quarter 2026 [...]
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
11/05/2026
Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch through Q1 2026 [...]
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
11/05/2026
In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), the event-driven primary disease-free survival (“DFS”) analysis is anticipated mid-year 2026 The [...]
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
11/05/2026
DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT ) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business [...]

Pages